MX2017000395A - Vacunas contra virus influenza y usos de las mismas. - Google Patents

Vacunas contra virus influenza y usos de las mismas.

Info

Publication number
MX2017000395A
MX2017000395A MX2017000395A MX2017000395A MX2017000395A MX 2017000395 A MX2017000395 A MX 2017000395A MX 2017000395 A MX2017000395 A MX 2017000395A MX 2017000395 A MX2017000395 A MX 2017000395A MX 2017000395 A MX2017000395 A MX 2017000395A
Authority
MX
Mexico
Prior art keywords
influenza virus
virus vaccines
methods
same
influenza
Prior art date
Application number
MX2017000395A
Other languages
English (en)
Inventor
Radosevic Katarina
Wilem Meijberg Jan
Wagner Michelle
Ding Zhaoqing
Impagliazzo Antonietta
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2017000395A publication Critical patent/MX2017000395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan polipéptidos de dominio de tallo de hemaglutinina de influenza multiméricos, métodos para proporcionar polipéptidos de dominio de tallo de hemaglutinina, composiciones que comprenden los mismos, vacunas que comprenden los mismos y métodos para su uso, en particular en la detección, la prevención y/o el tratamiento de influenza.
MX2017000395A 2014-07-10 2015-07-09 Vacunas contra virus influenza y usos de las mismas. MX2017000395A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19
PCT/EP2015/065663 WO2016005482A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
MX2017000395A true MX2017000395A (es) 2018-02-08

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000395A MX2017000395A (es) 2014-07-10 2015-07-09 Vacunas contra virus influenza y usos de las mismas.

Country Status (17)

Country Link
US (1) US10117925B2 (es)
EP (1) EP3166963B1 (es)
JP (1) JP7094103B2 (es)
KR (1) KR102463632B1 (es)
CN (1) CN107074912B (es)
AU (1) AU2015286723B2 (es)
BR (1) BR112016030577A8 (es)
CA (1) CA2953451C (es)
CL (1) CL2017000064A1 (es)
EA (1) EA035375B1 (es)
MX (1) MX2017000395A (es)
MY (1) MY182440A (es)
PE (1) PE20170291A1 (es)
PH (1) PH12016502468B1 (es)
SG (1) SG11201610456UA (es)
WO (1) WO2016005482A1 (es)
ZA (1) ZA201700165B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102461538B1 (ko) 2014-07-10 2022-10-31 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
KR20190056382A (ko) 2016-09-02 2019-05-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
US11447526B2 (en) 2018-01-23 2022-09-20 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US11576964B2 (en) * 2018-03-28 2023-02-14 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
US20210353738A1 (en) * 2018-09-21 2021-11-18 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
AU2020342463A1 (en) 2019-09-05 2022-03-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
CA3190070A1 (en) * 2020-09-07 2022-03-10 Martijn Alexander LANGEREIS Ha stem vaccine for ha antibody-positive targets
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
EP3248615A1 (en) * 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
US8900585B2 (en) * 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
MX346206B (es) 2011-07-14 2017-03-09 Crucell Holland Bv Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
SG11201402633UA (en) * 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
AU2014273173B2 (en) * 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102461538B1 (ko) 2014-07-10 2022-10-31 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도

Also Published As

Publication number Publication date
PE20170291A1 (es) 2017-03-26
US10117925B2 (en) 2018-11-06
US20170189519A1 (en) 2017-07-06
EA201692467A1 (ru) 2017-05-31
ZA201700165B (en) 2019-06-26
EA035375B1 (ru) 2020-06-03
KR20170027846A (ko) 2017-03-10
JP7094103B2 (ja) 2022-07-01
BR112016030577A8 (pt) 2021-07-20
EP3166963B1 (en) 2020-04-22
KR102463632B1 (ko) 2022-11-03
AU2015286723A1 (en) 2017-01-12
AU2015286723B2 (en) 2019-11-21
PH12016502468A1 (en) 2017-04-10
PH12016502468B1 (en) 2017-04-10
WO2016005482A1 (en) 2016-01-14
CA2953451A1 (en) 2016-01-14
EP3166963A1 (en) 2017-05-17
BR112016030577A2 (pt) 2017-10-31
JP2017521073A (ja) 2017-08-03
MY182440A (en) 2021-01-25
CN107074912A (zh) 2017-08-18
CA2953451C (en) 2023-09-19
SG11201610456UA (en) 2017-01-27
CN107074912B (zh) 2021-10-29
CL2017000064A1 (es) 2017-11-10

Similar Documents

Publication Publication Date Title
PH12016502468B1 (en) Influenza virus vaccines and uses thereof
PH12016502500A1 (en) Influenza virus vaccines and uses thereof
IL247309A0 (en) Preparations for inhibiting virus replication and methods for their preparation and use
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
IL286265A (en) A new tilapia virus and its uses
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
IL284242A (en) Gingerpine lysine suppressants, preparations containing them and their uses
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
IL246643A0 (en) Preparations and kits for the treatment of immunodeficiency virus/acquired immunodeficiency syndrome
EP3236997A4 (en) Dengue virus vaccine compositions and methods of use thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
ZA201700164B (en) Influenza virus vaccines and uses thereof
IL249705A0 (en) Influenza virus vaccines and their uses
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
TR201402220A2 (tr) Hemaglütinin esteraz baskılama niteliği sergileyen pikroretosit türevlerini ihtiva eden bir kompozisyon ve bu kompozisyonun viral enfeksiyonların tedavisinde kullanımı.